A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-31

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the respective placebos in adult patients with gout.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels

NCT05745727

Gout

COMPLETED PHASE1

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout

NCT03635957

Gout

COMPLETED PHASE4

Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

NCT04511702

Chronic Uncontrolled Gout Gout Uncontrolled Gout

COMPLETED PHASE4

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

NCT03994731

Gout

COMPLETED PHASE4

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

NCT06229145

Gout

ACTIVE_NOT_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will evaluate the efficacy, safety, tolerability, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of PRX-115 (a recombinant pegylated Uricase) in adult patients with gout. Participants will receive PRX-115 by intravenous (IV) infusions according to different treatment schedules, with and without the immunomodulator methotrexate (MTX).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gout

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Multiple IV infusions at a fixed dose per infusion, at different treatment intervals . For different dosing regimens, PRX-115 will be tested with and without the immunomodulator, MTX.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

E8W with MTX

IV infusion of PRX-115 every 8 weeks (E8W) for a total of 3 doses + 3 doses of PRX-115 placebo every alternating 8 weeks with MTX

Group Type EXPERIMENTAL

PRX-115

Intervention Type BIOLOGICAL

intravenous (IV) infusion

Methotrexate (MTX)

Intervention Type DRUG

Oral MTX 15 mg weekly

placebo E4W

infusion of PRX-115 placebo every 4 weeks (E4W) for a total of 6 doses with placebo-MTX

Group Type PLACEBO_COMPARATOR

PRX-115 placebo

Intervention Type OTHER

intravenous (IV) infusion

Placebo-Methotrexate

Intervention Type OTHER

Oral Placebo-MTX weekly

placebo E6W

IV infusion of PRX-115 placebo every 6 weeks (E6W) for a total of 4 doses with placebo-MTX

Group Type PLACEBO_COMPARATOR

PRX-115 placebo

Intervention Type OTHER

intravenous (IV) infusion

Placebo-Methotrexate

Intervention Type OTHER

Oral Placebo-MTX weekly

E6W with MTX

IV infusion of PRX-115 every 6 weeks (E6W) for a total of 4 doses with MTX

Group Type EXPERIMENTAL

PRX-115

Intervention Type BIOLOGICAL

intravenous (IV) infusion

Methotrexate (MTX)

Intervention Type DRUG

Oral MTX 15 mg weekly

E4W with MTX

IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with MTX

Group Type EXPERIMENTAL

PRX-115

Intervention Type BIOLOGICAL

intravenous (IV) infusion

Methotrexate (MTX)

Intervention Type DRUG

Oral MTX 15 mg weekly

E4W with placebo-MTX

IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with placebo-MTX

Group Type EXPERIMENTAL

PRX-115

Intervention Type BIOLOGICAL

intravenous (IV) infusion

Placebo-Methotrexate

Intervention Type OTHER

Oral Placebo-MTX weekly

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRX-115

intravenous (IV) infusion

Intervention Type BIOLOGICAL

Methotrexate (MTX)

Oral MTX 15 mg weekly

Intervention Type DRUG

PRX-115 placebo

intravenous (IV) infusion

Intervention Type OTHER

Placebo-Methotrexate

Oral Placebo-MTX weekly

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females ≥18 years of age.
2. Weight within the range of 50.0 - 150.0 kg.
3. Gout patients who failed to normalize sUA (\<7 mg/dL) with or without xanthine oxidase inhibitors or uricosuric agent or have contraindications to these drugs.
4. Willing to discontinue any oral ULT
5. Females who are sterile, postmenopausal, or non-pregnant and using birth control methods.

Exclusion Criteria

1. Any condition known to have arthritis as a clinical manifestation.
2. Positive testing for HBV,HCV, or HIV.
3. The patient is a pregnant or lactating female or plans to become pregnant during the study period.
4. Known allergy or sensitivity to the injected proteins, including pegylated products.
5. Prior exposure to any experimental or marketed uricase.
6. Patient treated with a medication known to have an influence on urate metabolism or clearance such as ULTs.
7. History of anaphylaxis, severe allergic reactions, or severe atopy.
8. G6PD deficiency or known catalase deficiency.
9. History of significant hematologic or autoimmune disorders within 5 years of Screening and/or patient is immunocompromised or treated with immunosuppressive medications.
10. Non-compensated CHF or hospitalization for CHF (Stage 3-4 NYHA Functional Class) within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled BP (\>160/100 mmHg) at screening and prior to randomization at Week -4 (Visit 1).
11. Current liver disease, as determined by ALT or AST levels above upper limit of normal at Screening Visit.
12. Chronic liver disease.
13. Hemoglobin \<11 g/dL, neutrophil count \<1500 /µl, or platelet count \<100,000 /µl.
14. Known severe pulmonary fibrosis, bronchiectasis or interstitial pneumonitis.
15. eGFR ≤ 40 mL/min/1.73m2 tested at Screening Visit. Kidney transplant or requires dialysis.
16. Known intolerance and/or known contraindication to MTX treatment or MTX treatment considered inappropriate
17. Has uncontrolled type 2 diabetes at Screening with HbA1c ≥8.5%. Patients with type 1 diabetes will be excluded.
18. Has known latent autoimmune diabetes of adult.
19. Immunocompromised state, regardless of etiology.
20. History or treatment of malignancy in the last 5 years, excluding localized, nonmelanoma skin cancers (e.g. basal or squamous cell)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No